Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Study summary

RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by making tumor cells more sensitive to radiation therapy. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells either by killing the cells or by stopping them from dividing and may also make tumor cells more sensitive to radiation therapy. PURPOSE: This phase I trial is studying the side effects and best dose of tipifarnib when given together with radiation therapy after combination chemotherapy in treating patients with stage III non-small cell lung cancer.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedcarboplatin and paclitaxel

Plus 2 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · Locally advanced

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Mar 13, 2019 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Abramson Cancer Center at Penn Medicine

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1
Sponsor: Abramson Cancer Center at Penn Medicine
Interventions being studied: Drug: carboplatin; Drug: paclitaxel; Drug: tipifarnib; Radiation: radiation therapy

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Disease setting

Locally advanced→

Treatment approach

Chemotherapy→Radiation therapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

DISEASE CHARACTERISTICS:
Histologically confirmed non-small cell lung cancer
Locally advanced (stage IIIA or IIIB) disease requiring radiotherapy
No malignant pleural effusion PATIENT CHARACTERISTICS: Age:
18 and over Performance status:
ECOG 0-2 Life expectancy:
Not specified Hematopoietic:
WBC at least 3,500/mm\^3
Platelet count at least 100,000/mm\^3 Hepatic:
Bilirubin no greater than 1.5 mg/dL
No grade 2 or greater elevation of liver function tests Renal:
Creatinine no greater than 1.5 times normal Pulmonary:
FEV\_1 at least 600 cc Other:
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
HIV negative
No grade 3 or 4 peripheral neuropathy
No known allergy to imidazole drugs (e.g., ketoconazole, miconazole, econazole, or terconazole) PRIOR CONCURRENT THERAPY: Biologic therapy:
Not specified Chemotherapy:
Up to 2 prior or concurrent carboplatin and paclitaxel chemotherapy regimens allowed Endocrine therapy:
Not specified Radiotherapy:
See Disease Characteristics
No prior thoracic radiotherapy Surgery:
At least 3 weeks since prior exploratory thoracotomy

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Abramson Cancer Center of the University of PennsylvaniaPhiladelphia, Pennsylvania

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 13, 2019. Always confirm current availability with the study team.

View original record ↗